A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-arm Trial to Assess the Efficacy, Safety, and Tolerability of Centanafadine Extended-release Capsules as Monotherapy or as Adjunct to SSRI in Adult Subjects With Major Depressive Disorder

This is a phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel-arm trial to assess the efficacy, safety, and tolerability of centanafadine once-daily (QD) extended-release (XR) capsules for the treatment of adult subjects diagnosed with Major Depressive Disorder (MDD).
The trial will evaluate the efficacy and safety of centanafadine QD XR capsules as monotherapy or as adjunct to the selective serotonin reuptake inhibitor (SSRI), escitalopram.

开始日期2022-09-12

申办/合作机构

Otsuka Pharmaceutical Development & Commercialization, Inc.

JPRN-jRCT2071220029 / Completed临床1期IIT

A Phase 1, Single-center, Parallel-group, Randomized, Placebo-controlled, Double-blind Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of EB-1020 in Healthy Adult Male Subjects

开始日期2022-07-15

申办/合作机构-

NCT05428033 / Recruiting临床3期

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Determine the Efficacy and Safety of Once Daily Centanafadine Capsules for the Treatment of Children With Attention-deficit/Hyperactivity Disorder (ADHD)

This trial will be conducted to evaluate the efficacy of centanafadine QD XR versus placebo in the treatment of child subjects (4 to 12 years, inclusive) with ADHD. The trial will consist of a screening period, a double-blind treatment period, and follow-up period.

开始日期2022-07-11

申办/合作机构

Otsuka Pharmaceutical Development & Commercialization, Inc.

100 项与 Centanafadine Hydrochloride 相关的临床结果

登录后查看更多信息

100 项与 Centanafadine Hydrochloride 相关的转化医学

登录后查看更多信息

100 项与 Centanafadine Hydrochloride 相关的专利（医药）

登录后查看更多信息

项与 Centanafadine Hydrochloride 相关的文献（医药）

2023-09-02·Expert review of clinical pharmacology

Pediatric attention deficit hyperactivity disorder (ADHD): 2022 updates on pharmacological management

Review

作者: Gamble, Hilary ; Carbone, Stephanie ; Faraone, Stephen V ; Gobbo, Anthony ; O'Connor, Lisa

INTRODUCTION:

Pediatric attention-deficit disorder (ADHD) impacts a significant percentage of the population world-wide. Pharmacologic treatments have been shown to be safe and effective for managing symptoms. Various medication formulations exist, and new medication agents are continually approved each year.

AREAS COVERED:

This article offers an overview of ADHD, an overview of both stimulant and non-stimulant medication options as well as an overview of stimulant misuse. It explores the medication mechanisms of action and side effect profiles, as well as offering an in-depth summary of the novel agents recently approved and soon-to-be approved for use in youth. PubMed and Medline were utilized. Search terms included children, adolescents, ADHD, and medication. FDA package inserts were reviewed for all medications.

EXPERT OPINION:

New formulations of medications include an evening administered, extended, and delayed-release form of methylphenidate (DR/ER MPH), a methylphenidate pro-drug (serdexmethylphenidate) and an amphetamine patch. The availability of a new SNRI (selective norepinephrine reuptake inhibitor), viloxazine extended-release (VER), and the pending approval of a triple reuptake inhibitor (centanafadine) provides welcome additions to the prescriber's toolbox.

2023-02-01·Journal of psychopharmacology (Oxford, England)

Neurotransmitter transporter occupancy following administration of centanafadine sustained-release tablets: A phase 1 study in healthy male adults

Article

作者: Angarita, Gustavo A ; Nabulsi, Nabeel ; Henry, Shannan ; Dias, Mark ; Huang, Yiyun ; Carson, Richard E ; Shoaf, Susan E ; Torres, Kristen ; Mehrotra, Shailly ; Gallezot, Jean-Dominique ; Matuskey, David

Background::

Centanafadine is an inhibitor of reuptake transporters for norepinephrine (NET), dopamine (DAT) and serotonin (SERT).

Aims::

This phase 1, adaptive-design positron emission tomography study investigated the occupancy time course of NET, DAT, and SERT and the relationship to centanafadine plasma concentrations.

Methods::

Healthy adult males received centanafadine sustained-release 400 mg/day for 4 days ( N = 6) or 800 mg in a single day ( N = 4). Assessments included safety monitoring; time course of occupancy of NET, DAT, and SERT; and centanafadine plasma concentrations.

Results::

Transporter occupancy was numerically higher for NET versus DAT or SERT. For NET, estimated (mean ± standard error [SE]) maximal observable target occupancy (TOmax) and concentration at half maximal occupancy (IC50) were 64 ± 7% and 132 ± 65 ng/mL, respectively, for all regions and 82 ± 13% and 135 ± 97 ng/mL after excluding the thalamus, which showed high nonspecific binding. For DAT and SERT, TOmax could not be established and was assumed to be 100%; estimated IC50 (mean ± SE) values were 1580 ± 186 ng/mL and 1,760 ± 309 ng/mL, respectively. For centanafadine, the estimated in vivo affinity ratio was 11.9 ± 6.0 (mean ± SE) for NET/DAT, 13.3 ± 7.0 for NET/SERT, and 1.1 ± 0.2 for DAT/SERT. DAT and SERT occupancies at a plasma concentration of 1400 ng/mL were estimated to be 47 and 44%, respectively.

Conclusions::

High occupancy at NET and moderate occupancy at DAT and SERT was observed at peak concentrations achieved following 400 mg total daily doses of centanafadine.

2022-09-01·Journal of clinical psychopharmacology

Efficacy, Safety, and Tolerability of Centanafadine Sustained-Release Tablets in Adults With Attention-Deficit/Hyperactivity Disorder

Article

作者: Angelicola, Mark ; Hobart, Mary ; Adams, Julie ; Kohegyi, Eva ; Adler, Lenard A. ; McQuade, Robert ; Liebowitz, Michael ; Madera-McDonough, Jessica ; Chang, Denise

Abstract:

Purpose/Background:

Centanafadine is an inhibitor of norepinephrine, dopamine, and serotonin reuptake transporters under investigation for the treatment of attention-deficit/hyperactivity disorder (ADHD).

Methods/Procedures:

Two phase 3 randomized, double-blind, placebo-controlled, parallel-group studies of 200 mg/d or 400 mg/d centanafadine sustained-release tablets versus placebo included adults (18–55 years of age) with a diagnosis of ADHD. The primary and key secondary efficacy endpoints were the change from baseline at day 42 in the Adult ADHD Investigator Symptom Rating Scale (AISRS) total score and the Clinical Global Impression–Severity of Illness Scale, respectively.

Findings/Results:

Subjects randomized in study 1 (centanafadine 200 mg/d, n = 149; centanafadine 400 mg/d, n = 149; placebo, n = 148) and study 2 (centanafadine 200 mg/d, n = 145; centanafadine 400 mg/d, n = 143; placebo, n = 142) had moderate to severe ADHD (mean AISRS total score, 38.7 [SD, 6.8] across both studies). At day 42, statistically significant least-squares mean differences in AISRS total score were observed in favor of centanafadine versus placebo in study 1 (200 mg/d: −3.16, P = 0.019; 400 mg/d: −2.74, P = 0.039) and study 2 (200 mg/d: −4.01, P = 0.002; 400 mg/d: −4.47, P = 0.001). Effect sizes versus placebo were −0.28 for 200 mg/d and −0.24 for 400 mg/d in study 1 and −0.37 for 200 mg/d and −0.40 for 400 mg/d in study 2. The overall rate of treatment-emergent adverse events (TEAEs) was low, but there was a small increase in TEAE occurrence with increasing dose. Incidences of serious TEAEs and abuse potential–related AEs were low.

Implications/Conclusions:

These are the first large-scale studies to demonstrate the efficacy and safety profiles of 200 mg/d and 400 mg/d centanafadine in adults with ADHD.

项与 Centanafadine Hydrochloride 相关的新闻（医药）

2024-07-30

·Pharmaceutical Technology

Collegium buys Ironshore for $525m and enter ADHD market

Collegium will also pay an additional $25m if the sales of Ironshore’s Jornay PM exceed the defined revenue expectation in 2025. Image Credit: tomertu / Shutterstock. Collegium Pharmaceuticals has signed a definitive agreement to acquire Ironshore Therapeutics in a bid to expand its portfolio beyond pain management. Collegium will pay $525m in cash to acquire outstanding shares of Ironshore. Following the transaction, Collegium will gain Ironshore’s US Food and Drug Administration (FDA)-approved therapy, Jornay PM (methylphenidate hydrochloride), for treating attention deficit hyperactivity disorder (ADHD) in patients aged six years and older. The company will also pay an additional $25m if the sales of Jornay PM exceed Collegium’s defined revenue expectations in 2025. The deal is expected to close in Q3 this year. Concurrent with the acquisition, Collegium also secured $646m as part of a five-year loan from Pharmakon Advisors, which, along with Collegium’s cash reserves, will fund the Ironshore acquisition. “The Ironshore acquisition is a unique opportunity to deliver a transaction that is immediately accretive to Collegium while meeting all of our strategic objectives through the addition of a growing commercial asset that diversifies our portfolio, has significant revenue potential and exclusivity into the 2030s,” said Michael Heffernan, chairman and interim president and chief executive officer of Collegium. Whilst there is a significant unmet need for new ADHD therapeutics, simulant treatments like Jornay PM face significant disadvantages due to their abuse potential and their prescribed use being limited to 30 days. See Also: Pipeline power: Sionna’s AbbVie deal could redefine CF therapeutics Podcast #5: Doing Digital Deals in Life Sciences | Deal Structure, Terms, and Series Conclusions The current market leader in the ADHD space is Takeda with two FDA-approved treatments, Vyvanse (lisdexamfetamine dimesylate) and Intuniv (guanfacine hydrochloride). However, the overall market for ADHD therapeutics across seven major markets (US, France, Germany, Italy, Spain, UK, and Japan) is expected to decline to $10.9bn by 2032 from $11.9bn in 2022, as per GlobalData analysis. This is mainly driven by the launch and uptake of generics. GlobalData is the parent company of Pharmaceutical Technology . Late-stage ADHD therapies in development include Otsuka Pharmaceuticals’ non-stimulant therapy centanafadine and Cingulate’s CTx-1301 (dexmethylphenidate) , a once-daily stimulant therapy. In October 2023, Otsuka reported positive data from two Phase III trials showing centanafadine’s efficacy in treating ADHD in adolescents and children.

临床结果临床3期并购上市批准

2023-11-01

·药明康德

治疗儿童多动症！潜在“first-in-class”新药双项3期试验达主要终点

日前，大冢制药（OtsukaPharmaceutical）宣布两项为期6周的3期临床试验的积极结果，该试验评估其潜在“first-in-class”疗法centanafadine治疗注意力缺陷/多动障碍（ADHD）青少年和儿童的疗效、安全性和耐受性。分析显示，centanafadine在两项试验中均达到主要终点，显著改善ADHD患者症状。大冢制药将与监管单位就试验结果进行讨论。 ADHD是一种神经发育障碍，定义为注意力不集中、紊乱和/或多动与冲动水平受损。ADHD没有已知的治愈方法，而且大多数人随着年龄的增长也不会痊愈。大约2/3或更多的ADHD儿童在成年后仍存有症状。 Centanafadine是一种在研、潜在“first-in-class"的去甲肾上腺素、多巴胺和5-羟色胺再摄取抑制剂（NDSRI），正在开发用于治疗儿童、青少年和成人ADHD患者。第一项试验是一项关键性、随机双盲、固定剂量的3期试验，旨在评估centanafadine对13-17岁ADHD青少年的疗效、安全性和耐受性。该试验达到主要终点，患者在ADHD-RS-5（用以评估儿童与青少年ADHD症状程度的量表）评分上较基线有所改善。与安慰剂相比，接受centanafadine治疗的患者在高剂量和低剂量（p=0.0099）以及高剂量（p=0.0006）centanafadine治疗组的平均疗效上均观察到统计学显著改善。低剂量centanafadine治疗组未达到统计学显著性。第二项试验是一项关键性、随机双盲、固定剂量3期试验，旨在评估centanafadine对6-12岁ADHD儿童的疗效、安全性和耐受性。该试验达到主要终点，患者在ADHD-RS-5量表评分上较基线有所改善。与安慰剂相比，接受centanafadine治疗的患者在高剂量和低剂量（p=0.0039）以及高剂量（p=0.0008）centanafadine治疗组的平均疗效上均观察到统计学显著改善。低剂量centanafadine治疗组未达到统计学显著性。两项研究的汇总分析中，最常观察到的centanafadine副作用（>2%且比安慰剂组更频繁）包括食欲下降、恶心、皮疹、疲乏、上腹痛和嗜睡。参考资料：[1] Otsuka Pharmaceutical Announces Positive Topline Results from Two Pivotal Phase 3 Trials of Centanafadine as a Treatment for Adolescents and Children with Attention-Deficit/Hyperactivity Disorder (ADHD). Retrieved October 30, 2023 from https://www.otsuka-us.com/news/otsuka-pharmaceutical-announces-positive-topline-results-two-pivotal-phase-3-trials 内容来源于网络，如有侵权，请联系删除。

临床结果临床3期

2023-10-31

·药研发

【药研发1101】舒泰神FcRn单抗获批自免病临床 | 恒瑞源正细胞疗法获批Ⅱ期临床...

「本文共：15条资讯，阅读时长约：3分钟」今日头条舒泰神FcRn单抗获批自免病临床。舒泰神1类生物药STSA-1301皮下注射液获国家药监局临床默示许可，拟开发用于治疗原发免疫性血小板减少症 (ITP) 。STSA-1301是一款重组抗人FcRn高亲和力人源化IgG4单克隆抗体。通过特异性结合FcRn，使其丧失和IgG结合的能力，加速IgG的降解，同时不影响IgM、IgA等其他类型抗体，从而有望达到治疗ITP等致病性IgG自身抗体介导的自身免疫性疾病的目的。国内药讯1.基石PD-L1单抗获附条件批准新适应症。基石药业PD-L1抗体舒格利单抗(择捷美®)获国家药监局附条件批准新适应症，单药用于治疗复发或难治性结外NK/T细胞淋巴瘤（R/R ENKTL）成人患者。在GEMSTONE-201研究中，舒格利单抗经IRRC评估的ORR达到46.2%，其中完全缓解率达到37.2%。舒格利单抗是全球首个获批用于R/R ENKTL患者的肿瘤免疫治疗药物，将改变现阶段R/R ENKTL患者的治疗格局。2.礼来Aβ单抗中国报产。礼来Aβ单抗donanemab的上市申请获国家药监局受理。Donanemab旨在通过与阿尔茨海默病（AD）患者大脑中沉积中的β淀粉样蛋白结合，以促进大脑中淀粉样蛋白斑块的清除。在Ⅲ期TRAILBLAZER-ALZ 2研究中，donanemab治疗组患者的iADRS评分和CDR-SB评分的下降速度分别减缓35%和36%，疾病进展速度延缓40%。今年年初，CDE已将Donanemab纳入突破性治疗品种，用于治疗早期症状性AD。3.康宁杰瑞PD-L1获批子宫内膜癌Ⅲ期临床。康宁杰瑞皮下注射PD-L1抗体恩沃利单抗（恩维达®）获FDA批准开展Ⅲ期临床（KN035-US-004），评估恩沃利单抗联合仑伐替尼对比卡铂-紫杉醇化疗用于一线治疗错配修复完整（pMMR）晚期或复发性子宫内膜癌患者的有效性与安全性。在美国，该新药还曾获得FDA授予的用于治疗晚期胆道癌及治疗软组织肉瘤的2项孤儿药资格。4.艾力斯EGFR-TKI获肺癌突破性疗法认定。艾力斯医药自主研发第三代EGFR-TKI创新药伏美替尼片获FDA突破性疗法认定，用于一线治疗EGFR 20外显子插入突变的局部晚期或转移性非鳞状非小细胞肺癌（NSCLC）患者。公布于WCLC2023年会上的Ⅰb期临床（FAVOUR）结果显示，经IRC评估，初治240mg组、经治240mg组、经治160mg组的确证客观缓解率（ORR）分别为78.6%、46.2%、38.5%，中位缓解持续时间（DoR）分别为15.2个月、13.1个月、9.7个月。5.恒瑞源正细胞疗法获批Ⅱ期临床。恒瑞源正1类生物制品多抗原自体免疫细胞注射液（MASCT-I）获国家药监局批准开展Ⅱ期临床，评价MASCT-I联合多柔比星和异环磷酰胺一线治疗晚期软组织肉瘤患者的有效性和安全性。MASCT-I的活性成份包括负载多种肿瘤相关抗原的DC细胞以及DC细胞活化扩增的自体效应T淋巴细胞。目前，MASCT-I也正在Ⅱ期临床中评估用于治疗尿路上皮癌的潜力。国际药讯1.诺华ETAR抑制剂IgA肾病III期临床积极。诺华高选择性内皮素A（ETA）受体抑制剂Atrasentan治疗IgA肾病的III期ALIGN研究达到主要终点。期中结果显示，与安慰剂相比，Atrasentan治疗组患者36周时蛋白与肌酐浓度比（UPCR）较基线的变化具有统计学意义的改善，患者的蛋白尿显著减少；其安全性与既往研究一致。诺华计划基于中期数据向FDA寻求加速批准上市。2.葛兰素史克PD-1抗体子宫内膜癌Ⅲ期临床成功。葛兰素史克PD-1抑制剂Jemperli（dostarlimab）联合标准化疗（卡铂和紫杉醇）、之后Jemperli单药的一线方案，在治疗原发性晚期或复发性子宫内膜癌的Ⅲ期临床RUBY达到总生存期（OS）的主要终点。在两个预定的亚群中（dMMR/MSI-H和MMRp/MSS），Jemperli组合均显著提高患者的OS。此前，该组合已达到无进展生存期（PFS）的主要终点，在dMMR/MSI-H亚群和总体患者群中分别降低72%和36%的疾病进展或死亡风险。此外，药物的安全性与已知研究一致。3.大冢多动症新药两项Ⅲ期临床积极。大冢制药潜在“first-in-class”疗法centanafadine治疗注意力缺陷/多动障碍的两项Ⅲ期临床均达到主要终点。与安慰剂相比，centanafadine治疗均能显著改善青少年（13-17岁）和儿童（6-12岁）患者的ADHD-RS-5量表评分，且药物安全性良好。Centanafadine是Neurovance公司（已被大冢制药收购）开发的一种甲肾上腺素、多巴胺和5-羟色胺再摄取抑制剂（NDSRI）。4.CSF1R激酶抑制剂TGCT关键Ⅲ期临床成功。Deciphera公司口服CSF1R激酶抑制剂vimseltinib治疗腱鞘巨细胞瘤（TGCT）患者的Ⅲ期（MOTION）试验达到主要和所有关键次要终点。在意向治疗（ITT）人群中，vimseltinib治疗组和安慰剂组第25周时的客观缓解率分别为40%（95% CI：29%-51%）和0%（95% CI：0%-9%），组间差异为40%（95% CI：29%-51%，p<0.0001）；药物的安全性与之前研究一致。该公司计划明年向FDA和欧盟递交上市申请。5.补体C3疗法眼科Ⅲ期临床见刊《柳叶刀》。Apellis公司在《柳叶刀》上发表其靶向C3补体蛋白的聚乙二醇化（PEGylated）双环肽疗法Syfovre（pegcetacoplan）治疗继发于年龄相关性黄斑变性（AMD）的地图样萎缩（GA）的Ⅲ期（OAKS和DERBY）研究积极结果。数据显示，每隔一个月和每月一次的Syfovre治疗均能显著减少GA病变的生长。今年2月，FDA已批准Syfovre用于治疗由AMD引起的地图样萎缩（GA）。6.DMD基因疗法Ⅲ期验证临床失败。Sarepta公司治疗杜氏肌营养不良（DMD）的基因疗法Elevidys在Ⅲ期验证性临床EMBARK中未达到主要终点。与安慰剂组相比，Elevidys治疗组患者的与运动功能相关的NSAA评分显示改善趋势，但不具统计学意义；而次要终点TTR和10MWR指标的统计则显著改善。今年6月，基于Elevidys在临床试验中显著提高患者肌肉中微抗肌萎缩蛋白的表达水平的替代终点结果，FDA已加速批准Elevidys上市。医药热点。1.辉瑞将裁员近800人。10月30日，根据新泽西州发布的《工人调整和再培训通知》（WARN），辉瑞将在新泽西州格拉德斯通裁员791人。这轮裁员计划预计将于2024年2月生效。10月16日，辉瑞因新冠业务下滑而下调了2023全年指引，将今年收入预期下调至580亿至610亿美元，比之前发布的指导性目标减少90亿美元。2.浙江中医药大学富春校区开工。近日，浙江中医药大学富春校区建设工程开工。这是浙江省重点建设项目、扩大有效投资“千项万亿”工程重大项目和公共服务“七优享”（学有优教）工程重大项目。项目总用地面积679.83亩，总建筑面积325000平方米。项目建成后，浙江中医药大学总部将搬迁至富春校区，进一步拓展办学空间、提升办学条件，助力建设一流中医药大学。3.复旦大学团队发布医生科普评价报告。据复旦大学发展研究院10月27日消息，复旦大学新闻学院孙少晶教授团队和复旦大学发展研究院王帆研究员团队历时半年多，通过对抖音、微博、微信三大社交媒体平台健康科普内容的抽样分析，完成《数字时代中国医生健康科普评价报告》。报告显示，在三个平台中，关于慢性疾病与生活方式的健康科普内容比较丰富，而心理健康等隐性健康话题的可见性与关注度明显不足。在阅读量较高的内容中，日常保健与疾病分析占比较高，癌症、中医药知识内容占较大比例，而心理疾病、疫苗等主题的内容相对较少。评审动态 1. CDE新药受理情况（10月31日) 2. FDA新药获批情况（北美10月27日）股市资讯上个交易日 A 股医药板块 +0.18%涨幅前三跌幅前三共同药业+20.00% 博瑞医药-13.80%普利制药+14.33% 达仁堂 -8.01%奥泰生物+13.38% 凯莱英 -7.96%【普利制药】2023年10月31日普利制药收到美国食品药品监督管理局签发的创新药注射用PL002的药物临床试验批件。【金城医药】金城医药集团股份有限公司全资子公司金城生物收到国家药品监督管理局下发的注射用丁二磺酸腺苷蛋氨酸的《药品注册证书》，同时其提交的丁二磺酸腺苷蛋氨酸原料药（无菌原料药）上市申请也获得了《化学原料药上市申请批准通知书》。【奥赛康】全资子公司江苏奥赛康替莫唑胺胶囊获得药品注册证书。- The End -戳“阅读原文”，了解更多医药研发及股市资讯。

孤儿药临床2期突破性疗法临床3期上市批准

100 项与 Centanafadine Hydrochloride 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D10698	Centanafadine Hydrochloride	-	DB14841

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
暴食症	临床3期	美国	Otsuka Pharmaceutical Development & Commercialization, Inc.	2023-02-14
注意缺陷障碍伴多动	临床3期	美国	Otsuka Pharmaceutical Development & Commercialization, Inc.	2022-02-02
注意缺陷障碍	临床3期	美国	Otsuka Pharmaceutical Development & Commercialization, Inc.	2019-01-16
重度抑郁症	临床2期	美国	Otsuka Pharmaceutical Development & Commercialization, Inc.	2022-09-12
戒烟	临床2期	美国	Otsuka Pharmaceutical Development & Commercialization, Inc.	2021-09-15
药物滥用	临床1期	美国	Neurovance, Inc.	2014-05-01
神经痛	临床前	美国	Euthymics Bioscience, Inc.	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


Pubmed	N/A	注意缺陷障碍伴多动	-	Centanafadine sustained-release	積鑰鹹窪膚積鹹製膚壓(簾鏇鏇網膚齋積觸簾獵) = 6.58-point difference 鹹顧鏇憲觸淵鏇襯窪遞 (淵獵選選齋窪鹽鏇構構 )	积极	2024-06-01
NCT05428033 (NEWS) 人工标引	临床3期	注意缺陷障碍伴多动	-	Centanafadine (high dose)	鬱齋遞構網網鬱顧蓋遞(構窪餘齋繭糧願鹹觸鏇) = In a pooled analysis across the two studies, the most frequently observed side effects for centanafadine (>2 percent and more frequent than placebo) included decreased appetite, nausea, rash, fatigue, upper abdominal pain and somnolence.Overall, the safety and tolerability results were consistent with the profile of centanafadine seen within the wider clinical development program. 鹽鹹構壓選觸壓醖鑰網 (鏇願網積憲齋築構鹽製 )	积极	2023-10-27
				Centanafadine (low dose)
NCT05257265 (NEWS) 人工标引	临床3期	注意缺陷障碍伴多动	-	Centanafadine (high dose)	糧餘簾壓鹽簾憲膚製衊(築構醖鏇顧鬱鹽糧壓構) = In a pooled analysis across the two studies, the most frequently observed side effects for centanafadine (>2 percent and more frequent than placebo) included decreased appetite, nausea, rash, fatigue, upper abdominal pain and somnolence.Overall, the safety and tolerability results were consistent with the profile of centanafadine seen within the wider clinical development program. 醖獵觸憲鏇廠餘壓憲製 (積獵顧壓襯醖衊憲築蓋 )	积极	2023-10-27
				Centanafadine (low dose)
NCT04081363 (CTgov)	临床2期	注意缺陷障碍伴多动	13	Centanafadine (Swallowed Capsules Cohort)	窪餘膚鏇選獵膚繭繭鑰(齋顧網廠夢顧鹹積鹹繭) = 鹽衊夢鹽範淵壓製範願顧憲廠齋網廠憲選願觸 (鹹鹽鑰鹽顧顧憲製遞獵, 蓋窪積餘憲鏇觸築範選 ~ 觸鑰膚鬱鬱選構淵蓋鏇) 更多	-	2023-01-13
				Centanafadine (Sprinkled Onto Applesauce Cohort)	窪餘膚鏇選獵膚繭繭鑰(齋顧網廠夢顧鹹積鹹繭) = 築蓋鹽憲鹹繭蓋蓋齋醖顧憲廠齋網廠憲選願觸 (鹹鹽鑰鹽顧顧憲製遞獵, 鹹獵衊鏇簾鹹衊壓觸範 ~ 淵窪構製糧廠艱繭窪衊) 更多
NCT03605836 (CTgov)	临床3期	注意缺陷障碍	590	Centanafadine SR (Double-blind Treatment Period: Centanafadine SR 200 mg)	繭獵觸鏇獵艱醖遞衊獵(膚糧窪網襯鬱襯網鑰製) = 蓋簾鏇衊遞選構廠鹽窪糧鹽憲製齋繭範齋範鹽 (繭壓願糧窪顧製鑰衊鏇, 壓艱遞積廠簾齋鹽齋製 ~ 窪淵製廠鑰艱膚鏇鹹積) 更多	-	2021-10-18
				Centanafadine SR (Double-blind Treatment Period: Centanafadine SR 400 mg)	繭獵觸鏇獵艱醖遞衊獵(膚糧窪網襯鬱襯網鑰製) = 願衊憲遞醖夢選醖網鬱糧鹽憲製齋繭範齋範鹽 (繭壓願糧窪顧製鑰衊鏇, 簾醖憲壓範鑰壓壓顧鹹 ~ 顧選鑰齋襯鏇淵蓋繭鏇) 更多
NCT01939353 (CTgov)	临床2期	注意缺陷障碍伴多动	45	Placebo+CTN SR	蓋壓廠襯製鹹衊鹽齋遞(餘窪鬱鬱鬱夢築築構遞) = 顧糧艱顧顧蓋獵醖鏇鏇築築鹽構鏇積鑰淵鹹鏇 (鹽蓋襯鏇衊遞繭餘餘積, 壓願廠獵壓齋窪夢蓋遞 ~ 襯觸窪構鬱鏇夢艱繭築) 更多	-	2021-10-18
NCT03605680 (CTgov)	临床3期	注意缺陷障碍	604	Centanafadine SR (Double-blind Treatment Period: Centanafadine SR 200 mg)	築鹹壓壓鏇淵齋製顧齋(憲願夢獵獵餘構獵艱衊) = 願餘淵壓鏇廠獵簾餘鬱艱鬱網壓網觸鏇艱獵淵 (壓襯選衊觸簾觸觸齋獵, 淵鹽膚範窪淵網製艱憲 ~ 艱鏇網窪鏇蓋獵鏇遞鬱) 更多	-	2021-05-05
				Centanafadine SR (Double-blind Treatment Period: Centanafadine SR 400 mg)	築鹹壓壓鏇淵齋製顧齋(憲願夢獵獵餘構獵艱衊) = 醖範鹹選顧製網繭窪窪艱鬱網壓網觸鏇艱獵淵 (壓襯選衊觸簾觸觸齋獵, 範範願淵積糧鏇獵製餘 ~ 製鏇鬱廠製淵鏇蓋鏇構) 更多